# Flywire Corp: financial statements, quarterly

FLYW · Nasdaq · CIK 1580560 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/flyw.md) · [Financials](/companies/flyw/financials.md) · [Filings](/companies/flyw/filings.md) · [Insiders](/companies/flyw/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/flyw/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [123](/filings/0000950170-24-123502.md) | [101 d](/filings/0001193125-26-067540.md) | [114](/filings/0000950170-25-065606.md) | [104](/filings/0000950170-25-104179.md) | [157](/filings/0001193125-25-274358.md) | [118 d](/filings/0001193125-26-067540.md) | [133](/filings/0001580560-26-000005.md) | [132](/filings/0001580560-26-000016.md) | [200](/filings/0001193125-25-274358.md) | [158 d](/filings/0001193125-26-067540.md) | [188](/filings/0001580560-26-000005.md) | [168](/filings/0001580560-26-000016.md) |
| Research and development | $m | [14.6](/filings/0000950170-24-123502.md) | [16.9 d](/filings/0001193125-26-067540.md) | [16.7](/filings/0000950170-25-065606.md) | [15.8](/filings/0000950170-25-104179.md) | [16.7](/filings/0001193125-25-274358.md) | [17.4 d](/filings/0001193125-26-067540.md) | [16.9](/filings/0001580560-26-000005.md) | [17.1](/filings/0001580560-26-000016.md) | [17.7](/filings/0001193125-25-274358.md) | [18.5 d](/filings/0001193125-26-067540.md) | [19.4](/filings/0001580560-26-000005.md) | [18.4](/filings/0001580560-26-000016.md) |
| Operating income | $m | [11.9](/filings/0000950170-24-123502.md) | [(10.0) d](/filings/0001193125-26-067540.md) | [(6.0)](/filings/0000950170-25-065606.md) | [(15.8)](/filings/0000950170-25-104179.md) | [20.3](/filings/0001193125-25-274358.md) | [(5.8) d](/filings/0001193125-26-067540.md) | [(11.0)](/filings/0001580560-26-000005.md) | [(9.0)](/filings/0001580560-26-000016.md) | [32.3](/filings/0001193125-25-274358.md) | [(1.0) d](/filings/0001193125-26-067540.md) | [10.8](/filings/0001580560-26-000005.md) | [(2.8)](/filings/0001580560-26-000016.md) |
| Interest expense | $m | [0.1](/filings/0000950170-24-123502.md) | [0.1 d](/filings/0000950170-24-021713.md) | [0.1](/filings/0000950170-24-054762.md) | [0.1](/filings/0000950170-24-091985.md) | [0.1](/filings/0000950170-24-123502.md) | [0.1 d](/filings/0001193125-26-067540.md) | [0.7](/filings/0001580560-26-000005.md) | [1.1](/filings/0001580560-26-000016.md) | [1.2](/filings/0001193125-25-274358.md) | [0.5 d](/filings/0001193125-26-067540.md) | [0.3](/filings/0001580560-26-000005.md) | [0.3](/filings/0001580560-26-000016.md) |
| Income tax | $m | [0.8](/filings/0000950170-24-123502.md) | [1.9 d](/filings/0001193125-26-067540.md) | [1.6](/filings/0000950170-25-065606.md) | [4.7](/filings/0000950170-25-104179.md) | [(8.3)](/filings/0001193125-25-274358.md) | [1.0 d](/filings/0001193125-26-067540.md) | [(0.9)](/filings/0001580560-26-000005.md) | [7.0](/filings/0001580560-26-000016.md) | [1.6](/filings/0001193125-25-274358.md) | [0.3 d](/filings/0001193125-26-067540.md) | [2.2](/filings/0001580560-26-000005.md) | [2.8](/filings/0001580560-26-000016.md) |
| Net income | $m | [10.6](/filings/0000950170-24-123502.md) | [1.3 d](/filings/0001193125-26-067540.md) | [(6.2)](/filings/0000950170-25-065606.md) | [(13.9)](/filings/0000950170-25-104179.md) | [38.9](/filings/0001193125-25-274358.md) | [(15.9) d](/filings/0001193125-26-067540.md) | [(4.2)](/filings/0001580560-26-000005.md) | [(12.0)](/filings/0001580560-26-000016.md) | [29.6](/filings/0001193125-25-274358.md) | [0.0 d](/filings/0001193125-26-067540.md) | [12.5](/filings/0001580560-26-000005.md) | [(8.1)](/filings/0001580560-26-000016.md) |
| Diluted EPS | $ per share | [0.08](/filings/0000950170-24-123502.md) | not reported | [(0.05)](/filings/0000950170-25-065606.md) | [(0.11)](/filings/0000950170-25-104179.md) | [0.30](/filings/0001193125-25-274358.md) | not reported | [(0.03)](/filings/0001580560-26-000005.md) | [(0.10)](/filings/0001580560-26-000016.md) | [0.23](/filings/0001193125-25-274358.md) | not reported | [0.10](/filings/0001580560-26-000005.md) | [(0.07)](/filings/0001580560-26-000016.md) |
| Basic EPS | $ per share | [0.09](/filings/0000950170-24-123502.md) | not reported | [(0.05)](/filings/0000950170-25-065606.md) | [(0.11)](/filings/0000950170-25-104179.md) | [0.31](/filings/0001193125-25-274358.md) | not reported | [(0.03)](/filings/0001580560-26-000005.md) | [(0.10)](/filings/0001580560-26-000016.md) | [0.24](/filings/0001193125-25-274358.md) | not reported | [0.10](/filings/0001580560-26-000005.md) | [(0.07)](/filings/0001580560-26-000016.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [638](/filings/0000950170-23-060405.md) | [655](/filings/0000950170-25-027078.md) | [619](/filings/0000950170-24-054762.md) | [539](/filings/0000950170-24-091985.md) | [565](/filings/0000950170-24-123502.md) | [495](/filings/0001193125-26-067540.md) | [191](/filings/0000950170-25-065606.md) | [250](/filings/0000950170-25-104179.md) | [355](/filings/0001193125-25-274358.md) | [330](/filings/0001580560-26-000016.md) | [312](/filings/0001580560-26-000005.md) | [282](/filings/0001580560-26-000016.md) |
| Current assets | $m | [762](/filings/0000950170-23-060405.md) | [816](/filings/0000950170-25-027078.md) | [739](/filings/0000950170-24-054762.md) | [711](/filings/0000950170-24-091985.md) | [876](/filings/0000950170-24-123502.md) | [763](/filings/0001193125-26-067540.md) | [397](/filings/0000950170-25-065606.md) | [449](/filings/0000950170-25-104179.md) | [606](/filings/0001193125-25-274358.md) | [602](/filings/0001580560-26-000016.md) | [512](/filings/0001580560-26-000005.md) | [504](/filings/0001580560-26-000016.md) |
| Total assets | $m | [982](/filings/0000950170-23-060405.md) | [1,080](/filings/0000950170-25-027078.md) | [999](/filings/0000950170-24-054762.md) | [999](/filings/0000950170-24-091985.md) | [1,240](/filings/0000950170-24-123502.md) | [1,122](/filings/0001193125-26-067540.md) | [1,060](/filings/0000950170-25-065606.md) | [1,114](/filings/0000950170-25-104179.md) | [1,260](/filings/0001193125-25-274358.md) | [1,253](/filings/0001580560-26-000016.md) | [1,162](/filings/0001580560-26-000005.md) | [1,163](/filings/0001580560-26-000016.md) |
| Current liabilities | $m | [192](/filings/0000950170-23-060405.md) | [274](/filings/0000950170-25-027078.md) | [183](/filings/0000950170-24-054762.md) | [177](/filings/0000950170-24-091985.md) | [375](/filings/0000950170-24-123502.md) | [290](/filings/0001193125-26-067540.md) | [196](/filings/0000950170-25-065606.md) | [240](/filings/0000950170-25-104179.md) | [396](/filings/0001193125-25-274358.md) | [402](/filings/0001580560-26-000016.md) | [294](/filings/0001580560-26-000005.md) | [331](/filings/0001580560-26-000016.md) |
| Total liabilities | $m | [207](/filings/0000950170-23-060405.md) | [294](/filings/0000950170-25-027078.md) | [202](/filings/0000950170-24-054762.md) | [196](/filings/0000950170-24-091985.md) | [397](/filings/0000950170-24-123502.md) | [308](/filings/0001193125-26-067540.md) | [276](/filings/0000950170-25-065606.md) | [322](/filings/0000950170-25-104179.md) | [431](/filings/0001193125-25-274358.md) | [418](/filings/0001580560-26-000016.md) | [310](/filings/0001580560-26-000005.md) | [346](/filings/0001580560-26-000016.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-274358.md) | [60.0](/filings/0000950170-25-065606.md) | [60.0](/filings/0000950170-25-104179.md) | [15.0](/filings/0001193125-25-274358.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [775](/filings/0000950170-24-123502.md) | [786](/filings/0001193125-26-067540.md) | [(797)](/filings/0000950170-25-104179.md) | [803](/filings/0001193125-25-274358.md) | [843](/filings/0001193125-25-274358.md) | [815](/filings/0001580560-26-000016.md) | [784](/filings/0001580560-26-000016.md) | [792](/filings/0001580560-26-000016.md) | [829](/filings/0001193125-25-274358.md) | [835](/filings/0001580560-26-000016.md) | [852](/filings/0001580560-26-000016.md) | [817](/filings/0001580560-26-000016.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [46.5 d](/filings/0000950170-24-123502.md) | [55.5 d](/filings/0001193125-26-067540.md) | [(38.1)](/filings/0000950170-25-065606.md) | [(19.3) d](/filings/0000950170-25-104179.md) | [185 d](/filings/0001193125-25-274358.md) | [(28.6) d](/filings/0001193125-26-067540.md) | [(80.8)](/filings/0001580560-26-000005.md) | [19.9 d](/filings/0001580560-26-000016.md) | [156 d](/filings/0001193125-25-274358.md) | [4.9 d](/filings/0001193125-26-067540.md) | [(15.8)](/filings/0001580560-26-000005.md) | [21.1 d](/filings/0001580560-26-000016.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-123502.md) | [0.1 d](/filings/0001193125-26-067540.md) | [0.3](/filings/0000950170-25-065606.md) | [0.3 d](/filings/0000950170-25-104179.md) | [0.2 d](/filings/0001193125-25-274358.md) | [0.1 d](/filings/0001193125-26-067540.md) | [0.2](/filings/0001580560-26-000005.md) | [0.5 d](/filings/0001580560-26-000016.md) | [0.2 d](/filings/0001193125-25-274358.md) | [0.4 d](/filings/0001193125-26-067540.md) | [0.1](/filings/0001580560-26-000005.md) | [0.3 d](/filings/0001580560-26-000016.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0000950170-25-065606.md) | [0.0 d](/filings/0000950170-25-104179.md) | [22.9 d](/filings/0001193125-25-274358.md) | not reported | [49.3](/filings/0001580560-26-000005.md) | [5.0 d](/filings/0001580560-26-000016.md) | [10.0 d](/filings/0001193125-25-274358.md) | not reported | [10.0](/filings/0001580560-26-000005.md) | [20.5 d](/filings/0001580560-26-000016.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [108](/filings/0000950170-23-060405.md) | [110](/filings/0000950170-24-054762.md) | [111](/filings/0000950170-24-091985.md) | [125](/filings/0000950170-24-123502.md) | [123](/filings/0000950170-25-065606.md) | [125](/filings/0000950170-25-104179.md) | [129](/filings/0001193125-25-274358.md) | [123](/filings/0001580560-26-000005.md) | [122](/filings/0001580560-26-000016.md) | [128](/filings/0001193125-25-274358.md) | [128](/filings/0001580560-26-000005.md) | [122](/filings/0001580560-26-000016.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.